Clinical trials: pMMR
First-line pMMR Endometrial Cancer
HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer
This is a multicenter, randomized, double-blind, placebo controlled Phase III clinical trial, aiming to evaluate the efficacy and safety of HB0025 combined with chemotherapy (paclitaxel plus carboplatin) versus placebo combined…
- Trial name
- NCT07902999
- Testing
- HB0025 Injection, Paclitaxel injection, Carboplatin injection
- Where
- 2 sites in China
- Volunteers
- 333 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Locally Advanced Colon Cancer, pMMR
Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS
Locally advanced colon cancer, particularly T4 disease or colon cancer with bulky nodes, carries a poor prognosis and limited efficacy with neoadjuvant chemotherapy.
- Trial name
- TORCH-C2 (NCT07877597)
- Testing
- short-course radiotherapy, Serplulimab, CapOx(Capecitabine+ Oxaliplatin)
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Fudan University
pMMR/MSS, Locally Advanced Rectal Carcinoma
16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer
Although standard neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer (LARC) effectively reduces local recurrence, radiotherapy-related toxicities and surgical complications severely impair patients' quality…
- Conditions
- pMMR/MSS, Locally Advanced Rectal Carcinoma, Fasting, Intermittent
- Trial name
- NCT07779694
- Testing
- 16-Hour Fasting, Serplulimab + chemotherapy
- Volunteers
- 51 people
- Sponsor
- Zhejiang University
Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC
Efficacy and safety of short-course radiotherapy in total neoadjuvant therapy combined with enlonstobart for pMMR locally advanced rectal cancer
- Trial name
- NCT07448077
- Testing
- Experimental: short-course radiotherapy and immunotherapy, Chemoradiotherapy
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Hebei Medical University Fourth Hospital
pMMR/MSS Advanced Colorectal Cancer
Clinical Study of MSH2-/- Tumor Cell Vaccines for Advanced pMMR Colorectal Cancer Patients
The goal of this clinical trial is to evaluate the safety and tolerability of an MSH2-/- tumor cell vaccine and to explore its preliminary antitumor activity and immunogenicity in adults with advanced proficient mismatch repair…
- Trial name
- NCT07510308
- Testing
- Low Dose MSH2-/- tumor cell vaccine, Medium Dose MSH2-/- tumor cell vaccine, High dose MSH2-/- tumor cell vaccine
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis
Botensilimab, Balstilimab, and SBRT in Colorectal Cancer
This is a single-arm pilot feasibility study evaluating the combination of Botensilimab and Balstilimab with Radiation Therapy (RT) in Non-Microsatellite Instability High (MSI-H) or Proficient Mismatch Repair (pMMR)…
- Trial name
- NCT07128355
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Botensilimab, Balstilimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts General Hospital
Rectal Cancer, pMMR (Microsatellite Stable Rectal Cancer)
Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer
This is a multicenter, phase III, randomized controlled trial. Eligible patients with pMMR/MSS locally advanced rectal cancer will be randomized in a 1:1 ratio to either the experimental group or the control group using…
- Trial name
- NCT07528209
- Testing
- Pucotenlimab combine with CAPOX, CAPOX
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer, Moderately Hypofractionated Radiotherapy
Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial
This study aims to observe and evaluate the efficacy and safety of moderately hypofractionated radiotherapy combined with chemotherapy and immunotherapy, compared with conventional neoadjuvant chemoradiotherapy, in patients with…
- Conditions
- Rectal Cancer, Moderately Hypofractionated Radiotherapy, Serplulimab, pMMR/MSS
- Trial name
- NCT07527520
- Testing
- Moderately Hypofractionated Radiotherapy, Serplulimab, CapOx+Long-course radiotherapy
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Fudan University
Colorectal Carcinoma, Oligometastases
SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
Background and Significance: Colorectal cancer (CRC) ranks as the third most common cancer and the second leading cause of cancer-related deaths globally.
- Conditions
- Colorectal Carcinoma, Oligometastases, pMMR, MSS
- Trial name
- NCT06850103
- Testing
- short-course radiotherapy, CAPEOX/XELOX, Serplulimab
- Where
- China
- Volunteers
- 51 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
pMMR, MSS
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
Colorectal cancer of Mismatch Repair-proficient (pMMR)/ Microsatellite Stability (MSS) accounts for approximately 85% of all colorectal cancer patients, which might be insensitive to immunotherapy.
- Conditions
- pMMR, MSS, MSI-L, Locally Advanced Rectal Carcinoma
- Trial name
- NCT05731726
- Testing
- Serplulimab, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang University
Refractory Metastatic Colorectal Cancer, pMMR
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
This is an open-label, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair…
- Conditions
- Refractory Metastatic Colorectal Cancer, pMMR, MSS
- Trial name
- NCT05733611
- Testing
- RP2, RP3, atezolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Replimune, Inc.
Endometrial Carcinoma (EC), pMMR
IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER
Endometrial carcinoma (EC) represents the most common gynecological malignancy in developed countries. Despite therapeutic advances, patients with advanced or recurrent disease still have a poor prognosis, with high recurrence…
- Conditions
- Endometrial Carcinoma (EC), pMMR, DMMR Cancer
- Trial name
- DEMETER (NCT07374809)
- Testing
- DNA methylation profiles
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- European Institute of Oncology
pMMR/MSS Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）
Safety and efficacy of Short-Course Radiotherapy Followed by Sequential Chemotherapy with or without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer.
- Trial name
- NCT07005570
- Testing
- Short-course radiotherapy followed by sequential chemotherapy combined with PD-1 monoclonal antibody and bevacizumab, Short-course radiotherapy followed by sequential chemotherapy
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Dechang Diao
Colorectal Cancer (CRC), pMMR/MSS Adenocarcinoma of the Colon or Rectum
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
Neoadjuvant immunotherapy has shown promising therapeutic effects in mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC).
- Trial name
- BASKETⅢ (NCT06791512)
- Testing
- mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody, mFOLFOX6
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Jun Huang
Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
The goal of this clinical trial is to find out if adding a PD-1 antibody (serplulimab) to FOLFOXIRI chemotherapy and radiotherapy works better than CAPOX chemotherapy with radiotherapy as total neoadjuvant therapy for adults with…
- Trial name
- NCT07277842
- Testing
- Serplulimab, FOLFOXIRI chemotherapy, CAPOX chemotherapy
- Where
- China
- Volunteers
- 382 people
- Sponsor
- Sun Yat-sen University
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer
QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer
This is a multicenter, prospective, phase II study evaluating total neoadjuvant therapy (TNT) consisting of short-course radiotherapy (SCRT; 5×5 Gy) followed by QL1706 (a bifunctional MabPair antibody targeting PD-1 and CTLA-4…
- Conditions
- Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer, Non-metastatic Rectal Cancer
- Trial name
- NCT07175636
- Testing
- Drug: QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy (SCRT)
- Volunteers
- 66 people
- Sponsor
- Sun Yat-sen University
Colon Cancer, MSS/pMMR
QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer
This is a single-arm, exploratory study enrolling participants with resectable stage III pMMR/MSS colon cancer. Eligible participants who provide written informed consent will receive four cycles of neoadjuvant treatment with…
- Conditions
- Colon Cancer, MSS/pMMR, QL1706
- Trial name
- NCT07156682
- Testing
- QL1706, XELOX
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Qilu Hospital of Shandong University
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers
This is an open-label, single-arm, investigator-initiated study conceived as a dose expansion cohort of the study D3-002, which evaluated ETC-159 in combination with pembrolizumab in solid tumors.
- Trial name
- ETC-159-02 (NCT06513624)
- Testing
- ETC-159, Pembrolizumab, Denosumab / Zoledronic Acid
- Where
- 2 sites in Singapore
- Volunteers
- 16 people
- Sponsor
- National University Hospital, Singapore
Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer
Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer
There are several basic findings in the previous studies: The levels of renin and aldosterone in the blood of cancer patients vary greatly among individuals, and the baseline levels of some patients are relatively higher than…
- Trial name
- EAPPA (NCT06992024)
- Testing
- Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine